Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nexavar meets liver cancer endpoint

Onyx (ONXX) gained $3.42 (10%) to $37.04 on Monday after it and partner

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE